Adams Diversified Equity Fund Inc. Buys New Position in Insulet Corporation (NASDAQ:PODD)

Adams Diversified Equity Fund Inc. acquired a new stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 40,700 shares of the medical instruments supplier's stock, valued at approximately $10,688,000. Adams Diversified Equity Fund Inc. owned approximately 0.06% of Insulet at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. SBI Securities Co. Ltd. purchased a new position in shares of Insulet during the 4th quarter valued at about $36,000. Itau Unibanco Holding S.A. purchased a new position in shares of Insulet during the 4th quarter valued at about $42,000. SRS Capital Advisors Inc. raised its holdings in shares of Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after buying an additional 56 shares in the last quarter. Assetmark Inc. raised its holdings in shares of Insulet by 1,447.1% during the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after buying an additional 246 shares in the last quarter. Finally, Coppell Advisory Solutions LLC raised its holdings in shares of Insulet by 135.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock valued at $74,000 after buying an additional 162 shares in the last quarter.

Insulet Stock Up 1.0%

Insulet stock traded up $3.25 on Friday, hitting $313.08. 760,290 shares of the stock traded hands, compared to its average volume of 714,720. The company has a current ratio of 4.47, a quick ratio of 3.63 and a debt-to-equity ratio of 1.21. The firm has a market cap of $22.03 billion, a P/E ratio of 56.31, a price-to-earnings-growth ratio of 2.77 and a beta of 1.37. The business's fifty day simple moving average is $297.69 and its 200 day simple moving average is $277.62. Insulet Corporation has a 1 year low of $173.00 and a 1 year high of $329.33.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, beating the consensus estimate of $0.81 by $0.21. The business had revenue of $569.00 million during the quarter, compared to analyst estimates of $543.20 million. Insulet had a return on equity of 22.25% and a net margin of 18.29%. The company's revenue for the quarter was up 28.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.73 earnings per share. As a group, sell-side analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PODD. Wolfe Research raised Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target on the stock in a research note on Tuesday, May 13th. Raymond James Financial reaffirmed an "outperform" rating and issued a $360.00 price target (up from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Sanford C. Bernstein reissued an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Wall Street Zen cut Insulet from a "buy" rating to a "hold" rating in a research note on Saturday, June 14th. Finally, Oppenheimer boosted their target price on Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Four research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $321.00.

Insiders Place Their Bets

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the business's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the transaction, the senior vice president now owns 23,180 shares of the company's stock, valued at approximately $7,382,134.60. The trade was a 18.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.39% of the stock is owned by insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.